Zepbound (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor ...
More than half of people with obesity have high blood pressure, according to the U.S. Centers for Disease Control and ...
Zepbound (tirzepatide) is a medication that helps people with obesity lose weight, but many people report trouble sleeping after taking it. Backing up these anecdotal reports, recent research has also ...
In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg of their previously achieved weight loss on average ...
A new report states that older adults using GLP-1 drugs may have a higher risk of loss of muscle mass, malnutrition, ...
Eligible patients may pay as low as $25 a month for their medicine INDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an access milestone in obesity care: all ...
Hosted on MSN
Eating with my daughter and my Zepbound
I’ve been on Zepbound since last August, a fact that I’ve shared with only four people besides my wife and medical professionals largely because of guys like Adam. On weekends, my wife and I and our ...
A new Medicare pathway, the Medicare GLP-1 Bridge program, makes Lilly's obesity medicines - a daily pill or the number 1 most prescribed injectable - accessible to ...
INDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an access milestone in obesity care: all three of the nation's largest pharmacy benefit managers (PBMs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results